Compare MHH & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | ATYR |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.5M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | MHH | ATYR |
|---|---|---|
| Price | $6.96 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 33.9K | ★ 2.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $196,657,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.50 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.24 | N/A |
| 52 Week Low | $6.20 | $0.64 |
| 52 Week High | $16.00 | $7.29 |
| Indicator | MHH | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 42.35 |
| Support Level | $6.79 | $0.69 |
| Resistance Level | $7.75 | $0.76 |
| Average True Range (ATR) | 0.50 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 48.79 | 29.49 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.